Associated Clinical Laboratories

Associated Clinical Laboratories was paid $25.89M by Medicaid between Jan 2018 and Dec 2024, across 292 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 12% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Pennsylvania

Rank by total paid#7 of 95

Median peer was paid$153K

This provider vs. median169×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	80,720	$686K
2019	73,089	$733K
2020	96,208	$1.77M
2021	344,308	$7.22M
2022	359,514	$6.91M
2023	342,033	$5.23M
2024incomplete	246,375	$3.34M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	12%	44,010	35,029	$3.21M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	7.6%	47,959	36,837	$1.97M
80050	General health panel	4.1%	27,442	27,105	$1.05M
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	3.7%	16,785	12,700	$954K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	3.4%	41,691	40,584	$885K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	3.3%	40,901	39,800	$844K
87631		3.0%	6,287	6,110	$780K
80061	Lipid panel	2.9%	72,869	71,653	$739K
80053	Comprehensive metabolic panel	2.8%	85,874	81,790	$731K
84443	Thyroid stimulating hormone (TSH)	2.8%	47,495	46,466	$719K
88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	2.6%	26,491	26,239	$672K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	2.5%	23,199	22,591	$647K

280 more codes

81420	Fetal chromosomal aneuploidy genomic sequence analysis panel	2.4%	1,455	$609K
0241U	Neonatal screening for hereditary disorders, genomic sequence analysis panel	2.3%	6,171	$606K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	1.8%	22,831	$476K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	1.4%	16,610	$366K
86480		1.3%	5,872	$344K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	1.3%	71,667	$339K
81220	CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants	1.2%	932	$313K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	1.2%	11,357	$311K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	1.1%	7,125	$291K
87086	Culture, bacterial; quantitative colony count, urine	1.0%	40,575	$268K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	1.0%	2,713	$267K
87480		<1%	12,587	$259K
87660		<1%	12,880	$252K
86803		<1%	16,619	$240K
80081		<1%	3,261	$237K
83036	Hemoglobin; glycosylated (A1C)	<1%	43,428	$234K
87088		<1%	33,769	$230K
87799		<1%	3,287	$222K
86003		<1%	1,835	$218K
84439		<1%	28,593	$187K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	1,642	$182K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	10,640	$171K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	2,352	$156K
80048	Basic metabolic panel (calcium, ionized)	<1%	23,074	$154K
87510		<1%	10,337	$151K
82728		<1%	14,548	$148K
84403		<1%	6,175	$141K
87536		<1%	1,754	$140K
84153		<1%	7,134	$119K
82607		<1%	12,398	$118K
87077		<1%	18,332	$116K
85027		<1%	19,215	$113K
87340		<1%	9,130	$112K
87522	Neg quan hep c or qual rna	<1%	3,772	$110K
87070		<1%	16,301	$103K
83540		<1%	15,104	$99K
87186		<1%	13,900	$94K
83655		<1%	10,482	$91K
84146		<1%	4,086	$85K
87081		<1%	18,243	$85K
87902		<1%	464	$83K
84402		<1%	3,627	$82K
86235		<1%	1,416	$82K
86787		<1%	4,752	$80K
80074		<1%	2,299	$79K
87512		<1%	3,287	$78K
82570		<1%	14,654	$77K
82043		<1%	13,164	$77K
81001		<1%	29,092	$74K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	1,558	$74K
84702		<1%	5,103	$68K
86038		<1%	5,790	$68K
86704		<1%	5,303	$68K
83550		<1%	14,295	$64K
84703		<1%	7,029	$62K
83001		<1%	3,721	$58K
84481		<1%	2,944	$58K
86618		<1%	3,118	$57K
82670		<1%	2,842	$55K
83970		<1%	1,601	$54K
83735		<1%	8,968	$53K
83002		<1%	3,389	$51K
82784		<1%	3,259	$50K
82652		<1%	1,356	$50K
82746		<1%	6,712	$50K
80348		<1%	10,808	$47K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	1,320	$46K
87209		<1%	2,583	$46K
81329		<1%	626	$46K
86317		<1%	2,735	$45K
86592		<1%	13,209	$44K
86706		<1%	3,742	$42K
80076		<1%	5,063	$39K
87481		<1%	1,792	$39K
82105		<1%	2,369	$38K
87634		<1%	685	$38K
81243		<1%	603	$37K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	510	$35K
82627		<1%	1,841	$35K
86665		<1%	1,033	$35K
36415	Collection of venous blood by venipuncture	<1%	42,549	$35K
84681		<1%	1,301	$33K
82248		<1%	5,956	$33K
80360		<1%	3,779	$32K
83880		<1%	1,199	$31K
86765		<1%	2,687	$30K
83525		<1%	2,947	$29K
86800		<1%	1,879	$28K
80349		<1%	7,874	$27K
85610		<1%	9,118	$27K
85652		<1%	11,359	$27K
81596		<1%	670	$26K
86140		<1%	9,329	$25K
86431		<1%	4,027	$25K
88185		<1%	89	$24K
86200		<1%	2,079	$24K
86708		<1%	2,095	$24K
82950		<1%	4,085	$23K
83498		<1%	1,211	$22K
88142		<1%	1,478	$22K
86360		<1%	657	$21K
86617		<1%	690	$21K
86376		<1%	2,625	$21K
82785		<1%	1,239	$19K
86361		<1%	774	$19K
84460		<1%	3,275	$18K
80373		<1%	4,998	$18K
81513		<1%	3,289	$18K
87177		<1%	2,569	$18K
84550		<1%	3,512	$18K
85004		<1%	2,908	$16K
82565		<1%	2,863	$16K
86039		<1%	1,316	$16K
84270		<1%	715	$15K
86696		<1%	902	$15K
86160		<1%	590	$15K
84450		<1%	2,598	$15K
80372		<1%	3,355	$15K
80164		<1%	1,089	$15K
86225		<1%	1,165	$14K
80361		<1%	4,715	$14K
80324		<1%	3,374	$14K
86664		<1%	881	$14K
82977		<1%	1,940	$14K
82533		<1%	1,239	$14K
83020		<1%	1,411	$14K
86334		<1%	637	$14K
83690		<1%	3,353	$14K
86850		<1%	2,029	$14K
84100		<1%	2,474	$13K
80362		<1%	5,323	$13K
84144		<1%	834	$13K
84630		<1%	1,070	$12K
83013		<1%	257	$12K
86762		<1%	812	$12K
86780		<1%	1,182	$12K
83921		<1%	728	$12K
84480		<1%	1,649	$11K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	275	$11K
85730		<1%	1,800	$11K
80069		<1%	1,490	$11K
82550		<1%	1,970	$11K
84590		<1%	937	$11K
87329		<1%	993	$10K
82542		<1%	557	$10K
81003		<1%	3,570	$10K
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	<1%	8,904	$10K
80355		<1%	5,676	$10K
86147		<1%	145	$10K
86695		<1%	835	$10K
84134		<1%	579	$9K
83516		<1%	495	$9K
87427		<1%	866	$9K
87625		<1%	277	$8K
85048		<1%	3,153	$8K
82150		<1%	2,212	$8K
80369		<1%	4,580	$8K
83721		<1%	1,406	$8K
86705		<1%	541	$8K
80366		<1%	4,039	$8K
80353		<1%	2,367	$8K
84165		<1%	674	$8K
84156		<1%	2,220	$8K
87075		<1%	997	$7K
80359		<1%	2,615	$7K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	22	$7K
86146		<1%	114	$7K
82951		<1%	579	$7K
87205		<1%	1,874	$7K
84436		<1%	1,913	$7K
80321		<1%	1,610	$7K
86769		<1%	311	$6K
85018		<1%	2,768	$6K
80346		<1%	1,609	$6K
87045		<1%	1,001	$6K
82672		<1%	471	$6K
85014		<1%	2,679	$6K
87255		<1%	213	$6K
84425		<1%	885	$6K
86364		<1%	497	$6K
83615		<1%	1,019	$6K
82947		<1%	1,769	$6K
82274		<1%	1,094	$6K
83993		<1%	301	$6K
80354		<1%	3,882	$5K
82247		<1%	895	$5K
86901		<1%	1,717	$5K
86735		<1%	599	$5K
86255		<1%	275	$5K
84520		<1%	1,097	$5K
80177		<1%	467	$5K
86341		<1%	131	$5K
86900		<1%	1,613	$5K
80335		<1%	1,437	$5K
87147		<1%	1,522	$5K
81025		<1%	1,212	$4K
80368		<1%	1,657	$4K
85041		<1%	1,511	$4K
80323		<1%	1,208	$4K
82040		<1%	1,294	$4K
80178		<1%	584	$4K
81512		<1%	42	$4K
80339		<1%	1,424	$4K
86308		<1%	625	$3K
88184		<1%	112	$3K
84432		<1%	174	$3K
87493		<1%	89	$3K
80365		<1%	1,473	$3K
84479		<1%	927	$3K
84482		<1%	165	$3K
85045		<1%	757	$3K
80175		<1%	240	$3K
82310		<1%	464	$3K
82747		<1%	407	$2K
84445		<1%	122	$2K
84305		<1%	98	$2K
86812		<1%	183	$2K
84154		<1%	157	$2K
82525		<1%	191	$2K
80438		<1%	85	$2K
82390		<1%	208	$2K
86300		<1%	57	$2K
82140		<1%	362	$2K
80299		<1%	132	$2K
82952		<1%	517	$2K
89055		<1%	362	$2K
83521		<1%	70	$1K
83021		<1%	75	$1K
87800		<1%	84	$1K
80197		<1%	127	$1K
82172		<1%	70	$1K
82653		<1%	78	$1K
82330		<1%	172	$1K
84132		<1%	246	$1K
84155		<1%	391	$1K
83718		<1%	240	$1K
83520		<1%	105	$1K
87046		<1%	332	$1K
82103		<1%	84	$1K
88307		<1%	25	$1K
87449		<1%	84	$1K
84207		<1%	38	$1K
82024		<1%	25	$993.51
82465		<1%	256	$896.10
86666		<1%	25	$852.37
87076		<1%	97	$797.09
86304		<1%	47	$754.03
87563		<1%	27	$666.05
88304		<1%	29	$662.00
82378		<1%	40	$632.80
85379		<1%	57	$535.83
86060		<1%	81	$473.24
84466		<1%	39	$438.02
83695		<1%	42	$402.77
86709		<1%	53	$383.41
85613		<1%	42	$365.64
86015		<1%	43	$361.50
85651		<1%	126	$312.83
85660		<1%	128	$291.51
83090		<1%	26	$271.77
86021		<1%	42	$224.84
81015		<1%	101	$209.88
86870		<1%	21	$156.54
80201		<1%	14	$141.17
83010		<1%	15	$125.84
86593		<1%	26	$123.09
86141		<1%	13	$117.79
83883		<1%	16	$115.34
80165		<1%	12	$110.80
82705		<1%	14	$98.94
85007		<1%	29	$89.74
84075		<1%	15	$87.86
86886		<1%	18	$84.28
85049		<1%	15	$38.64
80374		0%	185	$0.00
3048F		0%	131	$0.00
3049F		0%	46	$0.00
3044F		0%	88	$0.00
83789		0%	20	$0.00
3050F		0%	47	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialGARTLAND, DANIEL (CEO)

Parent organizationQUEST DIAGNOSTICS INCORPORATED